As of 2024-12-14, the Relative Valuation of BridgeBio Pharma Inc (BBIO) is (51.78) USD. This relative valuation is based on P/E multiples. With the latest stock price at 27.49 USD, the upside of BridgeBio Pharma Inc based on Relative Valuation is -288.4%.
The range of the Relative Valuation is (50.11) - (56.43) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.6x - 28.9x | 22.3x |
| Forward P/E multiples | 20.0x - 24.3x | 22.3x |
| Fair Price | (50.11) - (56.43) | (51.78) |
| Upside | -282.3% - -305.3% | -288.4% |
| Date | P/E |
| 2024-12-11 | -12.48 |
| 2024-12-10 | -12.51 |
| 2024-12-09 | -12.70 |
| 2024-12-06 | -12.40 |
| 2024-12-05 | -11.48 |
| 2024-12-04 | -11.67 |
| 2024-12-03 | -11.45 |
| 2024-12-02 | -11.45 |
| 2024-11-29 | -11.67 |
| 2024-11-27 | -11.84 |
| 2024-11-26 | -11.39 |
| 2024-11-25 | -11.71 |
| 2024-11-22 | -10.09 |
| 2024-11-21 | -10.01 |
| 2024-11-20 | -9.92 |
| 2024-11-19 | -9.71 |
| 2024-11-18 | -9.62 |
| 2024-11-15 | -10.21 |
| 2024-11-14 | -10.38 |
| 2024-11-13 | -10.68 |
| 2024-11-12 | -10.60 |
| 2024-11-11 | -11.25 |
| 2024-11-08 | -11.67 |
| 2024-11-07 | -11.14 |
| 2024-11-06 | -11.03 |
| 2024-11-05 | -10.99 |
| 2024-11-04 | -10.85 |
| 2024-11-01 | -10.97 |
| 2024-10-31 | -10.08 |
| 2024-10-30 | -10.24 |
| 2024-10-29 | -10.55 |
| 2024-10-28 | -10.52 |
| 2024-10-25 | -10.27 |
| 2024-10-24 | -10.41 |
| 2024-10-23 | -10.53 |
| 2024-10-22 | -10.74 |
| 2024-10-21 | -10.83 |
| 2024-10-18 | -11.21 |
| 2024-10-17 | -11.28 |
| 2024-10-16 | -11.34 |
| 2024-10-15 | -10.93 |
| 2024-10-14 | -11.10 |
| 2024-10-11 | -11.15 |
| 2024-10-10 | -10.75 |
| 2024-10-09 | -10.07 |
| 2024-10-08 | -10.65 |
| 2024-10-07 | -10.70 |
| 2024-10-04 | -10.87 |
| 2024-10-03 | -11.04 |
| 2024-10-02 | -10.80 |